Resumen de Seguimiento farmacoterapéutico de pacientes en tratamiento con imipenem/cilastastina y meropenem
Mª Pilar Ortega García, Sandra Villanueva Herraiz, Esther Rodríguez Murphy, Ana Zapater García
Objective: To evaluate pharmaceutical interventions (PI) resulting from the pharmacotherapeutic follow-up of non-critical adult patients treated with imipenem/cilastatin and meropenem. Method: Retrospective analysis study (June 2008-March 2009) of those PIs generated by the use of carbapenems. Results: 103 PIs (40 imipenem/cilastatin, 63 meropenem). In 80.6% of them the treatment was empirical. Main PIs: unapproved indication by the Infections Commission (IC) (35% imipenem/cilastatin, 44% meropenem), empirical treatment longer than 10 days (25% imipenem/cilastatin, 21% meropenem), and isolation of microorganisms sensitive to narrow-spectrum antibiotics (23% imipenem/cilastatin, 25% meropenem). The acceptance rate was 40% for imipenem/cilastatin and 25% for meropenem. The median number of treatment days and cost/patient were significantly lower when the PI was accepted. Conclusions: The empirical use and the use outside of the approved indications by the IC are quite high. The acceptance was greater when there was an intervention in prolonged treatments, and reduced the treatment duration and cost/patient
